POXEL Fundamental Analysis - POXEL SA

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to POXEL. POXEL was compared to 83 industry peers in the Biotechnology industry. POXEL has a bad profitability rating. Also its financial health evaluation is rather negative. POXEL does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

POXEL had negative earnings in the past year.

POXEL had a positive operating cash flow in the past year.

In the past 5 years POXEL always reported negative net income.

In the past 5 years POXEL always reported negative operating cash flow.

1.2 Ratios

POXEL has a Return On Assets of -272.29%. This is amonst the worse of the industry: POXEL underperforms 91.57% of its industry peers.

		Industry Rank	Sector Rank
ROA	-272.29%
ROE	N/A
ROIC	N/A

ROA(3y)-313.52%

ROA(5y)-206.55%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

POXEL's Gross Margin of 52.02% is in line compared to the rest of the industry. POXEL outperforms 50.60% of its industry peers.

In the last couple of years the Gross Margin of POXEL has declined.

The Profit Margin and Operating Margin are not available for POXEL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	52.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-17.62%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, POXEL has more shares outstanding

The number of shares outstanding for POXEL has been increased compared to 5 years ago.

The debt/assets ratio for POXEL has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -31.55, we must say that POXEL is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of POXEL (-31.55) is worse than 81.93% of its industry peers.

POXEL has a debt to FCF ratio of 74.74. This is a negative value and a sign of low solvency as POXEL would need 74.74 years to pay back of all of its debts.

The Debt to FCF ratio of POXEL (74.74) is better than 77.11% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	74.74
Altman-Z	-31.55

ROIC/WACCN/A

WACC11.07%

2.3 Liquidity

POXEL has a Current Ratio of 0.26. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.

POXEL has a Current ratio of 0.26. This is amonst the worse of the industry: POXEL underperforms 90.36% of its industry peers.

POXEL has a Quick Ratio of 0.26. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.

POXEL has a Quick ratio of 0.26. This is amonst the worse of the industry: POXEL underperforms 90.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.26
Quick Ratio	0.26

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

POXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.29%, which is quite impressive.

Looking at the last year, POXEL shows a very strong growth in Revenue. The Revenue has grown by 249.95%.

The Revenue for POXEL have been decreasing by -24.22% on average. This is quite bad

EPS 1Y (TTM)38.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%71.15%

Revenue 1Y (TTM)249.95%

Revenue growth 3Y-20.88%

Revenue growth 5Y-24.22%

Sales Q2Q%87.87%

3.2 Future

POXEL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.44% yearly.

Based on estimates for the next years, POXEL will show a very negative growth in Revenue. The Revenue will decrease by -18.07% on average per year.

EPS Next Y-10.48%

EPS Next 2Y-21.44%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-79.58%

Revenue Next 2Y-18.07%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

POXEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for POXEL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of POXEL indicates a rather cheap valuation: POXEL is cheaper than 91.57% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	16.14
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as POXEL's earnings are expected to decrease with -21.44% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-21.44%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

POXEL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

POXEL SA

EPA:POXEL (1/13/2026, 2:24:38 PM)

0.245

+0 (+1.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06

Earnings (Next)04-20 2026-04-20/amc

Inst Owners4.99%

Inst Owner ChangeN/A

Ins Owners3.45%

Ins Owner ChangeN/A

Market Cap13.17M

Revenue(TTM)7.66M

Net Income(TTM)-13.62M

Analysts84.44

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.72
P/FCF	16.14
P/OCF	16.14
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.26

EYN/A

EPS(NY)-1.74

Fwd EYN/A

FCF(TTM)0.02

FCFY6.2%

OCF(TTM)0.02

OCFY6.2%

SpS0.14

BVpS-1.14

TBVpS-1.14

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-272.29%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	52.02%
FCFM	10.66%

ROA(3y)-313.52%

ROA(5y)-206.55%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-17.62%

GM growth 5YN/A

F-Score5

Asset Turnover1.53

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	74.74
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.26
Quick Ratio	0.26
Altman-Z	-31.55

F-Score5

WACC11.07%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)38.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%71.15%

EPS Next Y-10.48%

EPS Next 2Y-21.44%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)249.95%

Revenue growth 3Y-20.88%

Revenue growth 5Y-24.22%

Sales Q2Q%87.87%

Revenue Next Year-79.58%

Revenue Next 2Y-18.07%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y80.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-223.51%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y104.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y104.93%

OCF growth 3YN/A

OCF growth 5YN/A

POXEL SA / POXEL.PA FAQ

What is the ChartMill fundamental rating of POXEL SA (POXEL.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to POXEL.PA.

What is the valuation status for POXEL stock?

ChartMill assigns a valuation rating of 2 / 10 to POXEL SA (POXEL.PA). This can be considered as Overvalued.

What is the profitability of POXEL stock?

POXEL SA (POXEL.PA) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for POXEL stock?

The Earnings per Share (EPS) of POXEL SA (POXEL.PA) is expected to decline by -10.48% in the next year.

POXEL SA (POXEL.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

POXEL SA / POXEL.PA FAQ

What is the ChartMill fundamental rating of POXEL SA (POXEL.PA) stock?

What is the valuation status for POXEL stock?

What is the profitability of POXEL stock?

Can you provide the expected EPS growth for POXEL stock?